Scholarlink

<p>Acute myeloid leukemia is an aggressive and heterogeneous disease characterized by abnormal proliferation of leukemic blast cells and niche remodeling. Traditional therapies fail to manage evolving and resistant AML subtypes. Next-generation immunotherapeutic interventions, such as CAR-T cells, immune checkpoint inhibitors, antibody-drug conjugates, and antibody-based therapeutics, target leukemic blast cells. This review aims to provide a comprehensive overview of the evolving landscapes of immunotherapeutic strategies, challenges, and breakthroughs in tackling AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evolving landscape of targeted immunotherapeutic interventions and CAR-T therapy for acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Tara Chand Yadav,
  • Shanid Mohiyuddin,
  • Gerhard C. Hildebrandt,
  • Senthilnathan Palaniyandi

摘要

Acute myeloid leukemia is an aggressive and heterogeneous disease characterized by abnormal proliferation of leukemic blast cells and niche remodeling. Traditional therapies fail to manage evolving and resistant AML subtypes. Next-generation immunotherapeutic interventions, such as CAR-T cells, immune checkpoint inhibitors, antibody-drug conjugates, and antibody-based therapeutics, target leukemic blast cells. This review aims to provide a comprehensive overview of the evolving landscapes of immunotherapeutic strategies, challenges, and breakthroughs in tackling AML.